bpc-157 human clinical trials safety regulatory status fda warning Regeneration or Risk? A Narrative Review of for Musculoskeletal Healing bpc-157 fda warning news FDA
Description
You have triggered the copper uglies: MMP overexpression from copper overload that degrades collagen instead of building it
The Case for Injectable BPC-157 Injectable administration bypasses digestion, allowing BPC-157 to circulate systemically and target distant tissues
Thus, interventions that increase NAD+ may slow aspects of the aging trajectory, and there is great interest in methods for cellular NAD+ restoration
& Reisner, S
